• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Changes in Some Vascular Biomarkers in Patients with Severe COVID-19 with Various Degrees of Pulmonary Hypertension.严重 COVID-19 患者不同程度肺动脉高压时某些血管生物标志物的变化。
Bull Exp Biol Med. 2022 Aug;173(4):433-436. doi: 10.1007/s10517-022-05581-5. Epub 2022 Sep 5.
2
B-type natriuretic peptide as a parameter for pulmonary hypertension in children. A systematic review.B型利钠肽作为儿童肺动脉高压的一个参数:一项系统评价
Eur J Pediatr. 2015 Oct;174(10):1267-75. doi: 10.1007/s00431-015-2619-0. Epub 2015 Aug 23.
3
Plasma N-terminal pro-brain natriuretic peptide: a prognostic marker in patients with chronic obstructive pulmonary disease.血浆 N 末端脑利钠肽前体:慢性阻塞性肺疾病患者的预后标志物。
Lung. 2012 Jun;190(3):271-6. doi: 10.1007/s00408-011-9363-7. Epub 2012 Jan 14.
4
Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis.比较脑利钠肽(BNP)和 N 端脑利钠肽前体(NT-proBNP)在系统性硬化症患者肺动脉高压筛查中的应用。
J Rheumatol. 2010 Oct;37(10):2064-70. doi: 10.3899/jrheum.090997. Epub 2010 Jul 15.
5
No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.在接受波生坦治疗的系统性硬化症相关肺动脉高压患者纵向队列中,N末端前脑钠肽无变化。
Int J Rheum Dis. 2017 Jan;20(1):90-96. doi: 10.1111/1756-185X.12721. Epub 2015 Jul 28.
6
[Natriuretic peptides as markers of development and prognosis of pulmonary hypertension severity in patients with chronic obstructive disease.].[利钠肽作为慢性阻塞性疾病患者肺动脉高压严重程度的发展及预后标志物。]
Klin Lab Diagn. 2018;63(6):333-337. doi: 10.18821/0869-2084-2018-63-6-333-337.
7
Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension.血清N末端脑钠肽作为肺动脉高压患者的预后参数。
Chest. 2006 May;129(5):1313-21. doi: 10.1378/chest.129.5.1313.
8
N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study.新型脑钠肽前体筛选算法在系统性硬化症相关肺动脉高压中的应用:一项病例对照研究。
Arthritis Res Ther. 2012 Jun 12;14(3):R143. doi: 10.1186/ar3876.
9
Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment.免疫反应性氨基末端脑钠肽前体(NT - PROBNP):心脏损伤的一种新标志物。
Clin Endocrinol (Oxf). 1997 Sep;47(3):287-96. doi: 10.1046/j.1365-2265.1997.2361058.x.
10
N-terminal pro-B-type natriuretic peptide for monitoring after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.N 末端 pro-B 型利钠肽在慢性血栓栓塞性肺动脉高压球囊肺血管成形术后的监测作用。
J Heart Lung Transplant. 2018 May;37(5):639-646. doi: 10.1016/j.healun.2017.12.006. Epub 2017 Dec 8.

引用本文的文献

1
Omics for searching plasma biomarkers associated with unfavorable COVID-19 progression in hypertensive patients.用于寻找与高血压患者COVID-19不良进展相关的血浆生物标志物的组学研究。
Sci Rep. 2025 Mar 25;15(1):10343. doi: 10.1038/s41598-025-94725-4.
2
Transpulmonary Plasma Endothelin-1 Arterial:Venous Ratio Differentiates Survivors from Non-Survivors in Critically Ill Patients with COVID-19-Induced Acute Respiratory Distress Syndrome.经肺血浆内皮素-1 动静脉比值区分 COVID-19 诱导的急性呼吸窘迫综合征危重症患者的幸存者与非幸存者。
Int J Mol Sci. 2024 Oct 2;25(19):10640. doi: 10.3390/ijms251910640.

本文引用的文献

1
Vascular Endothelial Damage in the Pathogenesis of Organ Injury in Severe COVID-19.严重 COVID-19 中器官损伤发病机制中的血管内皮损伤。
Arterioscler Thromb Vasc Biol. 2021 May 5;41(5):1760-1773. doi: 10.1161/ATVBAHA.120.315595. Epub 2021 Feb 25.
2
Blood nitrate and nitrite modulating nitric oxide bioavailability: Potential therapeutic functions in COVID-19.血液硝酸盐和亚硝酸盐调节一氧化氮生物利用度:在 COVID-19 中的潜在治疗作用。
Nitric Oxide. 2020 Oct 1;103:29-30. doi: 10.1016/j.niox.2020.07.005. Epub 2020 Jul 23.
3
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.新型冠状病毒肺炎的肺血管内皮细胞炎症、血栓形成和血管生成。
N Engl J Med. 2020 Jul 9;383(2):120-128. doi: 10.1056/NEJMoa2015432. Epub 2020 May 21.
4
COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.COVID-19 与心血管系统:对风险评估、诊断和治疗选择的影响。
Cardiovasc Res. 2020 Aug 1;116(10):1666-1687. doi: 10.1093/cvr/cvaa106.
5
Inhaled NO and COVID-19.吸入一氧化氮与新型冠状病毒肺炎
Br J Pharmacol. 2020 Aug;177(16):3848-3849. doi: 10.1111/bph.15085. Epub 2020 May 10.
6
COVID-19 and Cardiovascular Disease.新型冠状病毒肺炎与心血管疾病。
Circulation. 2020 May 19;141(20):1648-1655. doi: 10.1161/CIRCULATIONAHA.120.046941. Epub 2020 Mar 21.
7
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.中国武汉严重 COVID-19 患者的临床病程和结局:一项单中心、回顾性、观察性研究。
Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24.
8
Hypoxic pulmonary vasoconstriction.低氧性肺血管收缩。
Physiol Rev. 2012 Jan;92(1):367-520. doi: 10.1152/physrev.00041.2010.
9
Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension.肺动脉高压患者发病和现患队列的生存情况。
Eur Respir J. 2010 Sep;36(3):549-55. doi: 10.1183/09031936.00057010. Epub 2010 Jun 18.
10
Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver.亚硝酸盐在心脏和肝脏体内缺血再灌注过程中的细胞保护作用。
J Clin Invest. 2005 May;115(5):1232-40. doi: 10.1172/JCI22493. Epub 2005 Apr 14.

严重 COVID-19 患者不同程度肺动脉高压时某些血管生物标志物的变化。

Changes in Some Vascular Biomarkers in Patients with Severe COVID-19 with Various Degrees of Pulmonary Hypertension.

机构信息

City Clinical Hospital No. 1, Chita, Russia.

Chita State Medical Academy, Ministry of Health of the Russian Academy, Chita, Russia.

出版信息

Bull Exp Biol Med. 2022 Aug;173(4):433-436. doi: 10.1007/s10517-022-05581-5. Epub 2022 Sep 5.

DOI:10.1007/s10517-022-05581-5
PMID:36058981
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9441327/
Abstract

The aim of the study was to evaluate the levels of cardiac biomarkers endothelin 1, B-natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (Nt-proBNP), NO, and NO in patients with COVID-19 pneumonia and various degrees of pulmonary hypertension. Group 1 included patients with pulmonary artery systolic pressure <25 mm Hg, group 2 with 25-40 mm Hg, and group 3 with 40-60 mm Hg. In the group of patients with pulmonary artery systolic pressure <25 mm Hg, the level of NT-proBNP was higher than in the rest two groups by 41.3% (p=0.015) and 38.2% (p=0.015), respectively. The levels of nitrites and nitrates in group 1 patients were lower: NO was reduced by 31.1% (p=0.026) and 62.8% (p=0.008), and NO was reduced by 28% (p=0.029) and by 54.6% (p=0.006), respectively. No other changes in the parameters in patients receiving oxygen therapy were found. These findings suggest that severe course of COVID-19 in patients with severe pulmonary hypertension is associated with impaired nitrite and nitrate metabolism and reduced levels of Nt-proBNP.

摘要

本研究旨在评估 COVID-19 肺炎和各种程度肺动脉高压患者的内皮素 1、B 型利钠肽(BNP)、氨基末端 B 型利钠肽前体(Nt-proBNP)、NO 和硝酸盐水平。第 1 组患者的肺动脉收缩压<25mmHg,第 2 组为 25-40mmHg,第 3 组为 40-60mmHg。在肺动脉收缩压<25mmHg 的患者组中,NT-proBNP 水平分别比其余两组高 41.3%(p=0.015)和 38.2%(p=0.015)。第 1 组患者的亚硝酸盐和硝酸盐水平较低:NO 分别减少 31.1%(p=0.026)和 62.8%(p=0.008),NO 分别减少 28%(p=0.029)和 54.6%(p=0.006)。接受氧疗的患者的其他参数没有变化。这些发现表明,严重 COVID-19 患者的严重肺动脉高压与亚硝酸盐和硝酸盐代谢受损以及 Nt-proBNP 水平降低有关。